Chunhong Hu
A5100624575- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Diagnosis and Treatment
- Head and Neck Cancer Studies
- Radiomics and Machine Learning in Medical Imaging
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Circular RNAs in diseases
- RNA modifications and cancer
- MicroRNA in disease regulation
- Epigenetics and DNA Methylation
- Gastric Cancer Management and Outcomes
- Inflammatory Biomarkers in Disease Prognosis
- Cancer-related molecular mechanisms research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lymphoma Diagnosis and Treatment
- Advanced X-ray and CT Imaging
- Cancer, Hypoxia, and Metabolism
- Cancer-related gene regulation
- Cerebrovascular and Carotid Artery Diseases
- Pancreatic and Hepatic Oncology Research
- Medical Imaging Techniques and Applications
- Colorectal and Anal Carcinomas
- Medical Imaging and Pathology Studies
Second Xiangya Hospital of Central South University
2016-2025
Central South University
2016-2025
First Affiliated Hospital of Soochow University
2019-2025
Soochow University
2013-2025
PLA Air Force Aviation University
2022-2024
Xiangya Hospital Central South University
2006-2024
Hunan Cancer Hospital
2021-2024
Tianjin Medical University
2013-2023
Zhejiang Gongshang University
2023
Nanchong Central Hospital
2023
Purpose The phase III BEYOND trial was undertaken to confirm in a Chinese patient population the efficacy seen with first-line bevacizumab plus platinum doublet chemotherapy globally conducted studies. Patients and Methods age ≥ 18 years locally advanced, metastatic, or recurrent advanced nonsquamous non–small-cell lung cancer (NSCLC) were randomly assigned receive carboplatin (area under curve, 6) intravenously paclitaxel (175 mg/m 2 ) (CP) on day 1 of each 3-week cycle, for ≤ six cycles,...
<h3>Importance</h3> This study demonstrates that tislelizumab in combination with chemotherapy is associated improved progression-free survival (PFS) patients advanced squamous non–small-cell lung cancer (sq-NSCLC). <h3>Objective</h3> To assess the efficacy and safety/tolerability of plus vs alone as first-line treatment for sq-NSCLC. <h3>Design, Setting, Participants</h3> open-label, randomized phase 3 clinical trial was conducted at 46 sites China between July 2018 June 2019 included...
Cetuximab in combination with chemotherapy is a standard-of-care first-line treatment regimen for patients
Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation epidermal growth factor receptor tyrosine kinase inhibitor approved in China. This double-blind phase III trial evaluated the efficacy and safety of aumolertinib compared with gefitinib as first-line treatment for locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC; ClinicalTrials.gov identifier: NCT03849768).Patients at 53 sites China were randomly assigned 1:1 to receive either (110 mg)...
Importance Gastric and gastroesophageal junction cancers are diagnosed in more than 1 million people worldwide annually, few effective treatments available. Sintilimab, a recombinant human IgG4 monoclonal antibody that binds to programmed cell death (PD-1), combination with chemotherapy, has demonstrated promising efficacy. Objective To compare overall survival of patients unresectable locally advanced or metastatic gastric who were treated sintilimab chemotherapy vs placebo chemotherapy....
Importance There are currently no therapies approved by the US Food and Drug Administration for nasopharyngeal carcinoma (NPC). Gemcitabine-cisplatin is current standard of care first-line treatment recurrent or metastatic NPC (RM-NPC). Objective To determine whether toripalimab in combination with gemcitabine-cisplatin will significantly improve progression-free survival overall as RM-NPC, compared alone. Design, Setting, Participants JUPITER-02 an international, multicenter, randomized,...
Abstract Emotional distress (ED), commonly characterized by symptoms of depression and/or anxiety, is prevalent in patients with cancer. Preclinical studies suggest that ED can impair antitumor immune responses, but few clinical have explored its relationship response to checkpoint inhibitors (ICIs). Here we report results from cohort 1 the prospective observational STRESS-LUNG study, which investigated association between and efficacy first-line treatment ICIs advanced non-small-cell lung...
Artificial intelligence (AI) is developing quickly in the medical field and can benefit both staff patients. The clinical decision support system Watson for Oncology (WFO) an outstanding representative AI field, it provide to cancer patients prompt treatment recommendations comparable with ones made by expert oncologists. WFO increasingly being used China, but limited reports on whether suitable Chinese patients, especially lung cancer, exist. Here, we report a retrospective study based...
Background: Although growth advantage of certain clones would ultimately translate into a clinically visible disease progression, radiological imaging does not reflect clonal evolution at molecular level. Circulating tumor DNA (ctDNA), validated as tool for mutation detection in lung cancer, could dynamic changes. We evaluated the utility ctDNA predictive and prognostic marker monitoring advanced non-small cell cancer (NSCLC) patients. Methods: This is multicenter prospective cohort study....
This study aims to assess the efficacy and safety of penpulimab (a humanized anti-PD-1 IgG1 antibody) with anlotinib in first-line treatment Chinese patients uHCC.In this open-label multicenter phase Ib/II trial, histologically or cytologically confirmed uHCC, without previous systemic treatment, aged 18-75 years old, classified as BCLC stage B (not amenable for locoregional therapy) C, Child-Pugh score ≤7 ECOG performance status ≤1 were enrolled. Patients received [200 mg intravenous (i.v.)...
Diagnosing and treating patients with multiple primary lung cancers (MPLCs) bring challenges to the clinic, preliminary evidence has revealed unsatisfying outcomes after targeted therapy immunotherapy. Therefore, we surveyed genomic profiles of MPLCs their possible associations tumor mutation burden (TMB), programmed death-ligand 1 (PD-L1), immune cell infiltration landscape.A total 112 surgically resected 294 tumors were eligible, 255 sequenced using a 1021-gene panel. Immunohistochemistry...
IntroductionZL-2306-005 is a randomized, double-blind, multicenter phase 3 study evaluating the efficacy and safety of niraparib, poly(adenosine diphosphate-ribose) polymerase inhibitor, as first-line maintenance therapy in Chinese patients with platinum-responsive, extensive-stage SCLC (ES-SCLC).MethodsPatients complete response (CR) or partial (PR) to standardized, platinum-based chemotherapy were randomized 2:1 receive niraparib placebo (300 mg [baseline body weight ≥ 77 kg, platelet...
Abstract Background Treatment options for refractory metastatic colorectal cancer (mCRC) were limited. Anlotinib is a novel multitarget tyrosine kinase inhibitor. ALTER0703 study was conducted to assess efficacy and safety of anlotinib patients with mCRC. Materials Methods This multicenter, double-blinded, placebo-controlled, randomized phase III trial involving 33 hospitals in China. Patients had taken at least two lines therapies 2:1 receive oral (12 mg/day; days 1–14; 21 per cycle) or...
Abstract Chemotherapy works synergistically with sonodynamic therapy in a multi‐functional system and is employed to improve the therapeutic outcomes of hepatocellular carcinoma. In this study, ultrasound‐responsive nanoparticles (USFNPs) are loaded dual drugs, doxorubicin, composite ultrasound‐sensitive agent, curcumin‐gold. The USFNPs modified an acid‐hydrolyzable polyethylene glycol outermost layer, making it stable blood normal tissues while peeling off acidic tumor microenvironment....
Abstract Background Recent evidence has demonstrated that abnormal expression and regulation of circular RNA (circRNAs) are involved in the occurrence development a variety tumors. The aim this study was to investigate effects circ_PPAPDC1A Osimertinib resistance NSCLC. Methods Human circRNAs microarray analysis conducted identify differentially expressed (DE) Osimertinib-acquired tissues effect on cell proliferation, invasion, migration, apoptosis assessed both vitro vivo. Dual-luciferase...
Watson for Oncology (WFO) is a artificial intelligence clinical decision-support system with evidence-based treatment options oncologists. WFO has been gradually used in China, but limited reports on whether suitable Chinese patients. This study aims to investigate the concordance of between and real practice Cervical cancer patients retrospectively. We retrospectively enrolled 300 cases cervical provides 246 supported cases. Real were defined as concordant if designated "recommended" or...